In an elegant study, Peccate et al. recently demonstrated that a pre-treatment of the skeletal muscle of mdx mice (the most common mouse model for DMD; Bulfield et al., 1984) with peptide-phosphorodiamidate morpholino (PPMO) antisense oligonucleotides targeting dystrophin was beneficial for a subsequent AAV-based exon-skipping therapy (Peccate et al., 2016). Here, DMD is linked to Duchenne muscular dystrophy.